We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




BBI Solutions to Showcase Technologies for Next-Generation Diagnostics

By LabMedica International staff writers
Posted on 15 Nov 2017
Immunoassay development and manufacturing specialist BBI Solutions (Cardiff, UK) will showcase its award-winning Morffi signal enhancement technology at the world’s largest medical trade fair, MEDICA 2017, which runs from November 13 to 16 in Dusseldorf, Germany. More...
The Morffi signal enhancement technology is a patent pending conjugate blocking technology that could provide a two-fold enhancement in the limit of detection in both plasma and urine as compared to existing gold conjugation methods; enabling lateral flow immunoassays to compete with traditional lab-based testing platforms.

Additionally, BBI Solutions, along with its sister company, BBI Group’s mobile arm, Novarum (Scotland, UK), will showcase their innovative mobile technology which allows users to read and share results of lateral flow diagnostic tests using just a smartphone. The company’s smartphone readers enable tests to be accurately read from the point of care, at a patient’s home or in remote and challenging environments, with the results shared securely with healthcare professionals or specific end-users.

“This is an incredibly exciting period of growth and innovation for the business. We’re looking forward to the opportunity to outline BBI Solutions’ enhanced capabilities and showcase the potential presented by our landmark Morffi technology,” said Liam Taylor, managing director of BBI Solutions. “The combined impact of BBI Solutions’ and Novarum’s technology offers an outstanding end-to-end solution that has the potential to revolutionize the lateral flow diagnostics landscape and we relish the chance to showcase this compelling proposition during the event.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.